Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals Hospital

Zhejiang Boner Medical Secures Over RMB 800 Million in Pre-IPO Financing for Strategic Expansion

Fineline Cube Nov 9, 2023

Zhejiang Boner Medical Investment Management Co., Ltd., known as Bang-er Orthopedics, a leading hospital investment...

Company Drug

ImmuneOnco Biopharmaceuticals’ Timdarpacept (IMM01) Earns Orphan Drug Designation for CMML

Fineline Cube Nov 9, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received orphan drug...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Peripheral Thrombus Suction Catheter

Fineline Cube Nov 9, 2023

Lifetech Scientific Corporation (HKG: 1302), a China-based medical device company, has announced that it has...

Company

Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth

Fineline Cube Nov 9, 2023

Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023,...

Company

Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call

Fineline Cube Nov 9, 2023

US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third...

Company Drug

Abbisko Therapeutics’ CD73 Inhibitor ABSK051 Clears for Phase I Clinical Trial in China

Fineline Cube Nov 9, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment

Fineline Cube Nov 9, 2023

The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...

Company Deals

Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy

Fineline Cube Nov 9, 2023

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Deals

CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships

Fineline Cube Nov 9, 2023

The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...

Company Deals

Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC

Fineline Cube Nov 8, 2023

Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report...

Company Deals

Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million

Fineline Cube Nov 8, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by...

Company Drug

Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial

Fineline Cube Nov 8, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...

Company

Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook

Fineline Cube Nov 8, 2023

Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...

Company Deals

AstraZeneca Expands China Presence with Over 30 Agreements at CIIE

Fineline Cube Nov 8, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...

Company

Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai

Fineline Cube Nov 8, 2023

S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...

Company Deals

Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China

Fineline Cube Nov 8, 2023

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...

Company Deals

Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China

Fineline Cube Nov 8, 2023

Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...

Company Deals

Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China

Fineline Cube Nov 8, 2023

Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...

Company Drug

Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012

Fineline Cube Nov 8, 2023

Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Deals Medical Device

Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology

Fineline Cube Nov 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...

Posts pagination

1 … 498 499 500 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.